SG11201604936TA - Quinazolin-thf-amines as pde1 inhibitors - Google Patents
Quinazolin-thf-amines as pde1 inhibitorsInfo
- Publication number
- SG11201604936TA SG11201604936TA SG11201604936TA SG11201604936TA SG11201604936TA SG 11201604936T A SG11201604936T A SG 11201604936TA SG 11201604936T A SG11201604936T A SG 11201604936TA SG 11201604936T A SG11201604936T A SG 11201604936TA SG 11201604936T A SG11201604936T A SG 11201604936TA
- Authority
- SG
- Singapore
- Prior art keywords
- quinazolin
- thf
- amines
- pde1 inhibitors
- pde1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300707 | 2013-12-19 | ||
| DKPA201400249 | 2014-05-06 | ||
| PCT/EP2014/078475 WO2015091805A1 (en) | 2013-12-19 | 2014-12-18 | Quinazolin-thf-amines as pde1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604936TA true SG11201604936TA (en) | 2016-07-28 |
Family
ID=52350066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604936TA SG11201604936TA (en) | 2013-12-19 | 2014-12-18 | Quinazolin-thf-amines as pde1 inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20150175584A1 (pt) |
| EP (1) | EP3083607B1 (pt) |
| JP (1) | JP6419832B2 (pt) |
| KR (1) | KR20160098269A (pt) |
| CN (1) | CN105829300B (pt) |
| AP (1) | AP2016009293A0 (pt) |
| AU (1) | AU2014368601B2 (pt) |
| BR (1) | BR112016013946A8 (pt) |
| CA (1) | CA2933299A1 (pt) |
| CL (1) | CL2016001488A1 (pt) |
| CR (1) | CR20160282A (pt) |
| DO (1) | DOP2016000152A (pt) |
| EA (1) | EA201691108A1 (pt) |
| EC (1) | ECSP16061208A (pt) |
| ES (1) | ES2728079T3 (pt) |
| GE (1) | GEP201706764B (pt) |
| IL (1) | IL246230A0 (pt) |
| MX (1) | MX2016007945A (pt) |
| PE (1) | PE20160855A1 (pt) |
| PH (1) | PH12016501173A1 (pt) |
| RU (1) | RU2016125315A (pt) |
| SG (1) | SG11201604936TA (pt) |
| SV (1) | SV2016005220A (pt) |
| TN (1) | TN2016000239A1 (pt) |
| TW (1) | TW201609713A (pt) |
| WO (1) | WO2015091805A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201609713A (zh) | 2013-12-19 | 2016-03-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺 |
| RU2692808C2 (ru) * | 2014-04-04 | 2019-06-27 | Х. Лундбекк А/С | Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1 |
| TWI729109B (zh) * | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| CN110337437B (zh) | 2016-12-28 | 2023-02-03 | 达特神经科学有限公司 | 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物 |
| KR20200108419A (ko) | 2017-11-27 | 2020-09-18 | 다트 뉴로사이언스, 엘엘씨 | Pde1 억제제로서의 치환된 푸라노피리미딘 화합물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040066788A (ko) * | 2001-08-31 | 2004-07-27 | 더 락커펠러 유니버시티 | 프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1ｂ 매개되는 신호의 조절 |
| ZA200507228B (en) * | 2003-04-01 | 2007-03-28 | Applied Research Systems | Inhibitors of phosphodiesterases in infertility |
| CA2565037A1 (en) * | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
| US20070093515A1 (en) * | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| WO2007096743A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| EP2279009A4 (en) * | 2008-05-05 | 2011-09-21 | Univ Rochester | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE |
| EP2434895A4 (en) * | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US8796180B2 (en) * | 2009-09-24 | 2014-08-05 | Basf Se | Aminoquinazoline compounds for combating invertebrate pests |
| TW201609713A (zh) | 2013-12-19 | 2016-03-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺 |
-
2014
- 2014-12-01 TW TW103141539A patent/TW201609713A/zh unknown
- 2014-12-18 ES ES14827431T patent/ES2728079T3/es active Active
- 2014-12-18 PE PE2016000825A patent/PE20160855A1/es not_active Application Discontinuation
- 2014-12-18 CA CA2933299A patent/CA2933299A1/en not_active Abandoned
- 2014-12-18 RU RU2016125315A patent/RU2016125315A/ru unknown
- 2014-12-18 AU AU2014368601A patent/AU2014368601B2/en not_active Expired - Fee Related
- 2014-12-18 TN TN2016000239A patent/TN2016000239A1/en unknown
- 2014-12-18 EP EP14827431.9A patent/EP3083607B1/en active Active
- 2014-12-18 BR BR112016013946A patent/BR112016013946A8/pt not_active IP Right Cessation
- 2014-12-18 JP JP2016541407A patent/JP6419832B2/ja active Active
- 2014-12-18 US US14/574,425 patent/US20150175584A1/en not_active Abandoned
- 2014-12-18 SG SG11201604936TA patent/SG11201604936TA/en unknown
- 2014-12-18 WO PCT/EP2014/078475 patent/WO2015091805A1/en active Application Filing
- 2014-12-18 EA EA201691108A patent/EA201691108A1/ru unknown
- 2014-12-18 MX MX2016007945A patent/MX2016007945A/es unknown
- 2014-12-18 AP AP2016009293A patent/AP2016009293A0/en unknown
- 2014-12-18 GE GEAP201414180A patent/GEP201706764B/en unknown
- 2014-12-18 CN CN201480068495.XA patent/CN105829300B/zh active Active
- 2014-12-18 CR CR20160282A patent/CR20160282A/es unknown
- 2014-12-18 US US15/105,647 patent/US9701665B2/en active Active
- 2014-12-18 KR KR1020167016258A patent/KR20160098269A/ko not_active Application Discontinuation
-
2016
- 2016-06-14 CL CL2016001488A patent/CL2016001488A1/es unknown
- 2016-06-15 IL IL246230A patent/IL246230A0/en not_active IP Right Cessation
- 2016-06-15 SV SV2016005220A patent/SV2016005220A/es unknown
- 2016-06-16 PH PH12016501173A patent/PH12016501173A1/en unknown
- 2016-06-17 DO DO2016000152A patent/DOP2016000152A/es unknown
- 2016-07-18 EC ECIEPI201661208A patent/ECSP16061208A/es unknown
-
2017
- 2017-06-05 US US15/614,104 patent/US10030007B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190373T1 (hr) | Inhibitori dnk-pk | |
| RS57306B1 (sr) | Inhibitori dnk-pk | |
| HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
| IL239827A0 (en) | Deoxyuridine triphosphatase inhibitors | |
| HK1216531A1 (zh) | 新的抑制劑 | |
| GB201314578D0 (en) | Bicyclic inhibitors | |
| EP2991654A4 (en) | NOVEL CONNECTIONS AS AN ERK HEMMER | |
| HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
| HK1222848A1 (zh) | 用作 抑制劑的吡咯並三嗪 | |
| IL240763A0 (en) | The halopyrazoles as thrombin inhibitors | |
| IL246230A0 (en) | Amines thf quinazoline as pde1 inhibitors | |
| HK1213885A1 (zh) | 作為 抑制劑的咪唑並-三嗪衍生物 | |
| EP2968324A4 (en) | SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS | |
| HK1217950A1 (zh) | 新型 抑制劑 | |
| GB201319432D0 (en) | Shifts | |
| GB201305503D0 (en) | Inhibitor |